Aprea Therapeutics Inc. raised about $97.8 million in gross proceeds from its IPO on the Nasdaq Global Select Market.
The Boston-based biopharmaceutical company sold 6,516,667 common shares at $15 apiece. This includes an additional 850,000 shares purchased by the underwriters as part of their overallotment option.
Aprea's shares began trading on the exchange under the ticker symbol APRE on Oct. 3.
J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as joint book-running managers for the offering.
Aprea Therapeutics develops therapies for blood cancers such as myelodysplastic syndromes and acute myeloid leukemia.
